Nivolumab in NSCLC: Latest evidence and clinical potential

Raghav Sundar, Byoung Chul Cho, Julie R. Brahmer, Ross A. Soo

Research output: Contribution to journalReview article

Abstract

New insight on the interaction between the immune system and tumor has identified the programmed death-1/programmed death-1 ligand pathway to be a key player in evading host immune response. The immune checkpoint modulator, nivolumab (BMS-936558/ONO-4538), is the first PD-1 inhibitor to gain regulatory approval, for the treatment of patients with unresectable melanoma. This review will discuss results from early phase studies of nivolumab in solid tumors including non-small cell lung cancer (NSCLC) as well as studies of nivolumab in combination with chemotherapy, other immune modulators and molecular targeted therapy in patients with NSCLC.

Original languageEnglish (US)
Pages (from-to)85-96
Number of pages12
JournalTherapeutic Advances in Medical Oncology
Volume7
Issue number2
DOIs
StatePublished - Mar 2015

    Fingerprint

Keywords

  • immune checkpoint modulator
  • nivolumab
  • non-small cell lung cancer
  • programmed death-1
  • programmed death-1 ligand

ASJC Scopus subject areas

  • Oncology

Cite this